Lumiera Health Inc. announced the signing of a distribution agreement with Fideschem International Ltd. that will enable Awaye™ to access the Vietnamese market which has a population of approximately 100 million people and a pain relief market forecasted to grow at >11.24% annually for the foreseeable future. As a part of the agreement, Fideschem will first obtain and maintain all regulatory requirements to allow the sales of Awaye™ in Vietman and then manage all sales and marketing initiatives. Based on the regulatory process to commercialize health products in Vietnam, Fideschem and Lumeira forecast sales to begin in 12 months.

Awaye™ provides a new generation of relief from acute and chronic pain by exploiting the CB2 receptors of the endocannabinoid system, the body's built-in pain and inflammation defense system. Awaye™ is a unique Health Canada approved topical cream that provides relief from pain through complimentary mechanisms of action not found in any other product currently available on the market.